Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire F Verschraegen

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Idrugs : the Investigational Drugs Journal|June 12, 2003
KW-2170 (Kyowa Hakko Kogyo)Claire F Verschraegen
Oncology (Williston Park, N.Y.)|July 12, 2002
Irinotecan for the treatment of cervical cancerClaire F Verschraegen
Expert Opinion on Drug Delivery|November 22, 2005
Alternative administration of camptothecin analoguesUrsa Glaberman, Ian Rabinowitz, Claire F Verschraegen
Obstetrics and Gynecology Clinics of North America|November 29, 2005
Malignant adnexal masses in pregnancyHamid Sayar, Catherine Lhomme, Claire F Verschraegen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 18, 2020
The Next Step in Your Career: Getting the Right Opportunity and the Right ContractClaire F Verschraegen, Yousif Abubakr, Mark Lee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Reply to M.C. Chamberlain and T.J. KruserClaire F Verschraegen, Alissa Thomas, Vincent Vinh-Hung
Anticancer Research|July 28, 2004
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomasQian Li, Claire F Verschraegen, John Mendoza, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 3, 2008
SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancersDavid A Mills, Houman M Fekrazad, Claire F Verschraegen
Seminars in Oncology|October 5, 2015
The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersAnne F Schott, John J Welch, Claire F Verschraegen, et al.
Cancer Investigation|November 25, 2003
Cisplatin and irinotecan (CPT-11) for peritoneal mesotheliomaDuc Thanh Le, Michael Deavers, Kelly Hunt, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Idrugs : the Investigational Drugs Journal|June 12, 2003
KW-2170 (Kyowa Hakko Kogyo)Claire F Verschraegen
Oncology (Williston Park, N.Y.)|July 12, 2002
Irinotecan for the treatment of cervical cancerClaire F Verschraegen
Expert Opinion on Drug Delivery|November 22, 2005
Alternative administration of camptothecin analoguesUrsa Glaberman, Ian Rabinowitz, Claire F Verschraegen
Obstetrics and Gynecology Clinics of North America|November 29, 2005
Malignant adnexal masses in pregnancyHamid Sayar, Catherine Lhomme, Claire F Verschraegen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 18, 2020
The Next Step in Your Career: Getting the Right Opportunity and the Right ContractClaire F Verschraegen, Yousif Abubakr, Mark Lee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Reply to M.C. Chamberlain and T.J. KruserClaire F Verschraegen, Alissa Thomas, Vincent Vinh-Hung
Anticancer Research|July 28, 2004
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomasQian Li, Claire F Verschraegen, John Mendoza, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 3, 2008
SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancersDavid A Mills, Houman M Fekrazad, Claire F Verschraegen
Seminars in Oncology|October 5, 2015
The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersAnne F Schott, John J Welch, Claire F Verschraegen, et al.
Cancer Investigation|November 25, 2003
Cisplatin and irinotecan (CPT-11) for peritoneal mesotheliomaDuc Thanh Le, Michael Deavers, Kelly Hunt, et al.
Pageof 7